ライフサイエンスコーパス: zoledronate

1 0.5 microM for the bisphosphonate inhibitor, zoledronate).

2 f animals with vehicle, OPG, alendronate, or zoledronate.

3 ased by OPG but not by either alendronate or zoledronate.

4 ighly active species such as minodronate and zoledronate.

5 Eight of 1001 subjects receiving zoledronate (0.8%) exhibited mild to severe AAU within 7

6 In contrast, treatment with zoledronate (100 microM) did not induce cell death, inst

7 ANK-Fc; 100 microg of OPG-Fc; or 5 microg of zoledronate 2 h before 1,25(OH)(2)D(3) challenge on day

8 Intravenous infusion of zoledronate 5 mg or placebo.

9 AAU occurring after intravenous infusion of zoledronate (5 mg).

10 T cells, a phenomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor

11 Zoledronate activates human Vgamma9Vdelta2 T cells, whic

12 dard adjuvant systemic therapy alone or with zoledronate administered at a dose of 4 mg for 19 doses

13 ophilic analogs of the bone-resorption drugs zoledronate and risedronate.

14 T lymphocytes by synthetic phosphoantigens, zoledronate, and a BTN3A1 Ab in the absence of an exogen

15 tivation of Vgamma9Vdelta2 T cells by HMBPP, zoledronate, and POM2-C-HMBP, but not by a partial agoni

16 e-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate on bone show that all side

17 HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.

18 ion concentrations, whereas pamidronate and zoledronate appear to act on the hFOB cells by a direct

19 Bisphosphonates such as alendronate and zoledronate are blockbuster drugs used to inhibit osteoc

20 crystal structures of HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.

21 All cases of AAU were from the zoledronate arm of the study, where the incidence was 0.

22 idence of 2.1% (95% CI, 0.9% to 3.3%) in the zoledronate arm.

23 armacologic inhibition of bone resorption by zoledronate attenuates inflammasome activation in mice.

24 either 30- micro g or 150- micro g doses of zoledronate before tumor implantation (pretreatment grou

25 P) site, not to the allosteric site, whereas zoledronate bound via Mg(2+) to the same site as seen in

26 uptake of AF-ALN or internalization of [14C]zoledronate but prevented the inhibitory effect of alend

27 Likewise, zoledronate caused a substantial delay in gammadelta T c

28 (EDTA)-demineralized dentin with or without zoledronate-containing primer (Zol-primer) pre-treatment

29 In the zoledronate-containing structures, taxodione and arenaro

30 stemic administration of the bisphosphonate, zoledronate, could prevent bone lysis and halt the proli

31 Pamidronate and zoledronate decreased hFOB cell proliferation with equal

32 acid phosphatase (TRAP) staining showed that zoledronate decreased osteoclastic numbers and that ther

33 Zoledronate did not affect the in vitro proliferation of

34 y suggest that treatment with pamidronate or zoledronate enhances the differentiation and bone-formin

35 f this study was to evaluate the efficacy of zoledronate in limiting the formation and/or progression

36 Both pamidronate and zoledronate increase hFOB cell bone formation, whereas n

37 memory phenotype, were sufficient to enable zoledronate-induced expansion of highly purified gammade

38 IL-18 was shown to enhance zoledronate-induced gammadelta T cell activation.

39 he potent nitrogen-containing bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a

40 However, zoledronate is associated with the occasional developmen

41 rly breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and improve survival.

42 dronate (n = 17) and pamidronate followed by zoledronate (n = 33).

43 Bisphosphonate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidro

44 In conclusion, zoledronate offers an additional inhibitory effect to th

45 nted the inhibitory effect of alendronate or zoledronate on Rap1A prenylation.

46 ed by OPG treatment, whereas alendronate and zoledronate only partially reduced these two parameters.

47 the Vgamma9(+) T cells in medium containing zoledronate or IPP strongly increased SF-derived fibrobl

48 s, similar to those observed with OPG-Fc and zoledronate (p < or = 0.01 vs controls).

49 ction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up time (P = .03),

50 s on Oral-QoL differed significantly between zoledronate patients and control patients.

51 The in vivo administration of zoledronate produced significant bone preservation but d

52 , DU145, and LNCaP cells with pamidronate or zoledronate significantly reduced the growth of all thre

53 nd to the same site as seen in the taxodione+zoledronate structure, but the second located to a more

54 rophosphate and the aminobisphosphonate drug zoledronate that causes intracellular accumulation of is

55 d bisphosphonate inhibitors, alendronate and zoledronate, that inhibit the consumption of DMADP and I

56 Zoledronate therapy deters whereas PTH therapy promotes

57 er, repletion of GGPP, which prevented acute zoledronate toxicity, and supplementation with IL-18, wh

58 sible cases of ONJ were reported, all in the zoledronate-treated patients.

59 man enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use.

60 Adjuvant zoledronate used in the intensive schedule studied in th

61 r transferrin), and uptake of AF-ALN or [14C]zoledronate was inhibited by dansylcadaverine, indicatin

62 cancer cell growth in the presence of serum, zoledronate was more potent under these conditions, disr

63 tibias implanted with the LAPC-9 cells, the zoledronate was not effective in halting the formation o

64 rabbit osteoclasts; uptake of AF-ALN or [14C]zoledronate was stimulated by the presence of Ca2+ and S

65 The zoledronate was very effective in limiting the formation

66 cting etidronate and the potent new analogue zoledronate, were also compared with the action of pamid

67 The most active compounds were found to be zoledronate (whose single-crystal X-ray structure is rep

68 The systemic administration of zoledronate with STI571 and paclitaxel produced a signif

69 imarily neutral pyridine side chain, whereas zoledronate (with an imidazole ring) binds more strongly

70 Zoledronate (ZOL) treatment induces intracellular accumu

71 Here, we studied fluvastatin (Fluva) and zoledronate (Zol), representative molecules of each clas

72 ey rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]